Home » Newsletters » BioWorld Science

BioWorld Science

April 27, 2015

View Archived Issues

Gene editing of human intestinal organoids as a model system for colorectal cancer

MRC Technology and NYU School of Medicine to develop antibody for inflammatory osteolysis

GTx licenses University of Tennessee SARD technology

Chugai Pharmaceutical reports on active first quarter of 2015

Novel PDE10 inhibitor demonstrates highly potent and selective tumor cell growth inhibitory activity

Amgen profiles progress of first quarter 2015

Lack of mitochondrial toxicity of AL-335 and AL-516

Positive European opinion on methylnaltrexone bromide for opioid-induced constipation

In vitro test first to detect psychiatric adverse events of drugs

Phase III success with single-dose dalbavancin regimen for Gram-positive skin infections

FDA accepts AbbVie's NDA for all-oral, interferon-free HCV regimen

MedImmune and Juno Therapeutics partner for immuno-oncology clinical trials

CUPID2 trial of Mydicar fails to meet endpoints

First clinical results on antibacterial OP-0595

Mitotech's antioxidant SkQ1 reduces symptoms of dry eye in phase II trial

R-Tech Ueno acquires rights to DE-105 from Santen Pharmaceutical

FDA approves Cyramza for metastatic colorectal cancer

Nissan Chemical patents new Cav3.2 inhibitors

Amgen discloses Nav1.7 inhibitors

Bayer Schering Pharma reports FXIa inhibitors

A*STAR discloses MNK1 and 2 inhibitors

Daewoong reports discovery of H+/K+-ATPase inhibitors

FDA grants orphan drug designation to GW's cannabidiol for neonatal hypoxic-ischemic encephalopathy

EMA committee recommends approval of Opdivo for advanced melanoma

European committee recommends approval of Hetlioz for non-24-hour sleep-wake disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 26, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 27, 2026.
Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease
BioWorld Science
Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...
Muted and missing M&As: JPM deals absent in 2026
BioWorld
For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...